The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Cancer Screening Molecular Tools

Fengting Yan

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

Staging Disease: How Oncologists Stage NSCLC

GRACE

I. Dagogo-Jack, M. Das, C. Jeffrey Yang

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

WCLC 2024 Insights: Augmented Imaging Techniques for Peripheral Nodu…

Insights from 2024 WCLC

C. Leong

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Total Health

S. Kazmi

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Year in Review: Precision Medicine

Vivek Subbiah

ADCs and Bispecific Inhibitors in NSCLC

Chul Kim

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante